Before to develop diagnostic nanoparticles bound to cetuximab (anti-EGFR antibody currently used in CRC), the level of EGFR expression on adenomas surface should be assessed and compared to normal colorectal mucosa or to other non adenomatous lesions. Here, EGFR is linked to colorectal carcinoma.